

Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following is the best description of TAR-200?**
 - Internal radioactive implant
 - Wafer-based chemotherapy implant
 - Intravesical drug delivery system for gemcitabine
 - Novel microsurgical technique
- 2. Which of the following therapies is FDA approved for patients with previously treated HER2-overexpressing advanced urothelial bladder cancer (UBC)?**
 - Tucatinib/trastuzumab
 - Trastuzumab deruxtecan
 - Neratinib
 - Disitamab vedotin
 - None of the above: HER2-targeted therapy is not approved for UBC
- 3. Which of the following serious adverse events is most commonly associated with trastuzumab deruxtecan?**
 - Cytokine release syndrome
 - Tumor lysis syndrome
 - Hearing loss
 - Interstitial lung disease
- 4. Approximately what proportion of cases of bladder cancer harbor a form of HER2 alteration?**
 - 2%
 - 20%
 - 50%
 - 70%
 - 90%
- 5. Disitamab vedotin is an antibody-drug conjugate targeting which of the following?**
 - Nectin-4
 - HER2
 - FGFR3
 - TROP2